content,keywords,test_description,title,"{""raw"":""You are a scientist with copy-editing skills tasked with refining the text of a scientific manuscript. Your goal is to revise the following paragraph from the Methods section.\n\nInput paragraph: {{ content }}\n\nRevised paragraph:"",""display"":""/home/miltondp/projects/others/manubot/manubot-ai-editor-evals/methods/prompts/baseline.txt"",""id"":""dbdbe966caae3b6a35435049407ecdbb26b866d5a60bf0e456744a0bc18f5ac9"",""provider"":""exec:python /home/miltondp/projects/others/manubot/manubot-ai-editor-evals/src/llm.py  --model anthropic=claude-3-opus-20240229"",""metrics"":{""score"":9.675,""testPassCount"":5,""testFailCount"":15,""assertPassCount"":145,""assertFailCount"":25,""totalLatencyMs"":14782,""tokenUsage"":{""total"":0,""prompt"":0,""completion"":0,""cached"":0},""namedScores"":{},""cost"":0}}","{""raw"":""You are a scientist with copy-editing skills tasked with refining the text of a scientific manuscript with title '{{ title }}' and keywords '{{ keywords }}.' Your goal is to revise the following paragraph from the Methods section to enhance clarity, reduce jargon, maintain a scholarly tone, and adhere to Markdown formatting. Your revision should: 1) preserve the original information as much as possible, with minimal changes to the text, 2) preserve technical details such as mathematical expressions, 3) ensure that equations (which could be numbered) are preserved and correctly defined, 4) preserve references to numbered equations, and 5) ensure most references to scientific articles are kept exactly as they appear in the original text; these references are crucial for academic integrity and may appear with the format \""[@TYPE:ID]\"" such as \""[@pmid:33931583; @doi:10.1101/2021.10.21.21265225; @pmid:31036433]\"".\n\nInput paragraph: {{ content }}\n\nRevised paragraph:"",""display"":""/home/miltondp/projects/others/manubot/manubot-ai-editor-evals/methods/prompts/candidate_with_metadata.txt"",""id"":""c357f426d8096fca34c9477212751fc056a5b5ef4294c917e72358475247bfeb"",""provider"":""exec:python /home/miltondp/projects/others/manubot/manubot-ai-editor-evals/src/llm.py  --model anthropic=claude-3-opus-20240229"",""metrics"":{""score"":10.28125,""testPassCount"":15,""testFailCount"":5,""assertPassCount"":165,""assertFailCount"":5,""totalLatencyMs"":14854,""tokenUsage"":{""total"":0,""prompt"":0,""completion"":0,""cached"":0},""namedScores"":{},""cost"":0}}","{""raw"":""You are a scientist with copy-editing skills tasked with refining the text of a scientific manuscript. Your goal is to revise the following paragraph from the Methods section to enhance clarity, reduce jargon, maintain a scholarly tone, and adhere to Markdown formatting. Your revision should: 1) preserve the original information as much as possible, with minimal changes to the text, 2) preserve technical details such as mathematical expressions, 3) ensure that equations (which could be numbered) are preserved and correctly defined, 4) preserve references to numbered equations, and 5) ensure most references to scientific articles are kept exactly as they appear in the original text; these references are crucial for academic integrity and may appear with the format \""[@TYPE:ID]\"" such as \""[@pmid:33931583; @doi:10.1101/2021.10.21.21265225; @pmid:31036433]\"".\n\nInput paragraph: {{ content }}\n\nRevised paragraph:"",""display"":""/home/miltondp/projects/others/manubot/manubot-ai-editor-evals/methods/prompts/candidate.txt"",""id"":""5455ec1f5a9652cb7ba31daceeffa11db4d075c888105c481683c678f87e4308"",""provider"":""exec:python /home/miltondp/projects/others/manubot/manubot-ai-editor-evals/src/llm.py  --model anthropic=claude-3-opus-20240229"",""metrics"":{""score"":10.28125,""testPassCount"":15,""testFailCount"":5,""assertPassCount"":165,""assertFailCount"":5,""totalLatencyMs"":14859,""tokenUsage"":{""total"":0,""prompt"":0,""completion"":0,""cached"":0},""namedScores"":{},""cost"":0}}"
"Here we briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, $X_a$ is the genotype of SNP $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves inline math,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.41)

Failed
---
Here is the revised paragraph:

We briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of SNP $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Fail Reason: Failed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed"
"Here we briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, $X_a$ is the genotype of SNP $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves inline math,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.41)

Failed
---
Here is the revised paragraph with improved clarity and formatting:

We briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of SNP $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with a mean equal to zero and a standard deviation equal to one.

Fail Reason: Failed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed"
"Here we briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, $X_a$ is the genotype of SNP $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves inline math,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.41)

Failed
---
Here is the revised paragraph with improved clarity and formatting:

We briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of SNP $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with a mean equal to zero and a standard deviation equal to one.

Fail Reason: Failed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed"
"Here we briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, $X_a$ is the genotype of SNP $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves inline math,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.41)

Failed
---
Here is the revised paragraph with improved clarity and formatting:

We briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of SNP $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Fail Reason: Failed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed"
"Here we briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, $X_a$ is the genotype of SNP $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves inline math,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.41)

Failed
---
Here is the revised paragraph with improvements to clarity, grammar, and formatting:

We briefly provide the details about these TWAS methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of SNP $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with a mean equal to zero and a standard deviation equal to one.

Fail Reason: Failed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed","[PASS] (0.47)

Here we briefly provide the details about these transcriptome-wide association study (TWAS) methods that are necessary to explain our regression framework later (see the referenced articles for more information). In the following, we refer to $\mathbf{y}$ as a vector of traits for $n$ individuals that is centered for convenience (so that no intercept is necessary); $\tilde{\mathbf{t}}_l = \sum_{a \in \mathrm{model}_l} w_{a}^{l} X_{a}$ is the gene's predicted expression for all individuals in tissue $l$, where $X_a$ is the genotype of single nucleotide polymorphism (SNP) $a$ and $w_{a}$ is its weight in the tissue prediction model $l$; and $\mathbf{t}_l$ is the standardized version of $\tilde{\mathbf{t}}_l$ with mean equal to zero and standard deviation equal to one.

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves numbered equations and references to articles,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{y}$ is the trait, $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $w_a^l$ is the weight of SNP $a$ in the gene expression model for tissue $l$, $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves numbered equations and references to articles,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.75)

Failed
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers increased or decreased disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{y}$ is the trait, $\mathbf{t}_l$ is the predicted expression of the gene in tissue $l$, $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $w_a^l$ is the weight of SNP $a$ in the prediction model for the gene's expression in tissue $l$, $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of the gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves numbered equations and references to articles,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.75)

Failed
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367] that uses only GWAS summary statistics to approximate PrediXcan results. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using the following expression:

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In both TWAS methods, the genotype variances and covariances are estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. S-PrediXcan provides tissue-specific direction of effects, indicating whether a higher or lower predicted expression of a gene confers more or less disease risk. We utilized these $z$-scores in our drug repurposing approach, which is described below.

Fail Reason: Failed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{y}$ is the trait, $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $w_a^l$ is the weight of SNP $a$ in the gene expression model for tissue $l$, $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves numbered equations and references to articles,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1], the summary version of PrediXcan [@doi:10.1038/ng.3367], models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers increased or decreased disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based extension of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{y}$ is the trait vector, $\mathbf{t}_l$ is the predicted gene expression vector for tissue $l$, $\gamma_l$ is the effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$, where $\hat{\gamma}_l$ is the estimated effect size and $\mathrm{se}(\hat{\gamma}_l)$ is its standard error.

While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $w_a^l$ is the weight of SNP $a$ in the gene expression model for tissue $l$, $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS, and $\mathrm{se}(\hat{\beta}_a)$ is its standard error. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted gene expression confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Preserves numbered equations and references to articles,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.75)

Failed
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (i.e., whether a higher or lower predicted expression of a gene confers increased or decreased disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{y}$ is the trait, $\mathbf{t}_l$ is the predicted expression of the gene in tissue $l$, $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $w_a^l$ is the weight of single nucleotide polymorphism (SNP) $a$ in the prediction model for the gene's expression in tissue $l$, $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of the gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.78)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model:

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression:

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where \mathbf{t}_l is the gene predicted expression in tissue $l$, $\beta_l$ is the estimated effect size or regression coefficient, and $\epsilon_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\Sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_l$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes incorrect math references,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.44)

Failed
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, $w_a^l$ is the weight of SNP $a$ in the model for tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted gene expression confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted gene expression confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where \mathbf{t}_l is the gene predicted expression in tissue $l$, $\beta_l$ is the estimated effect size or regression coefficient, and $\epsilon_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\Sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_l$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes incorrect math references,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.44)

Failed
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS, and $w_a^l$ are the tissue-specific SNP weights. In both TWAS methods, the genotype variances and covariances are estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted gene expression confers increased or decreased disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted gene expression confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue. PrediXcan uses the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. 

While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted gene expression confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where \mathbf{t}_l is the gene predicted expression in tissue $l$, $\beta_l$ is the estimated effect size or regression coefficient, and $\epsilon_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\Sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_l$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes incorrect math references,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in \mathrm{model}_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS, and $w_a^l$ are the weights of the prediction model for tissue $l$. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific directions of effect (for instance, whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted gene expression confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where \mathbf{t}_l is the gene predicted expression in tissue $l$, $\beta_l$ is the estimated effect size or regression coefficient, and $\epsilon_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\Sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_l$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes incorrect math references,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, $w_a^l$ is the weight of SNP $a$ in the model for tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for example, whether higher or lower predicted expression of a gene confers increased or decreased disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in \mathrm{model}_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where \mathbf{t}_l is the gene predicted expression in tissue $l$, $\beta_l$ is the estimated effect size or regression coefficient, and $\epsilon_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\Sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_l$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes incorrect math references,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1], the summary version of PrediXcan [@doi:10.1038/ng.3367], models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in \mathrm{model}_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS, and $w_a^l$ are the tissue-specific SNP weights. In these TWAS methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (i.e., whether higher or lower predicted gene expression confers increased or decreased disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted gene expression in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted gene expression confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed","[PASS] (0.47)

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t}_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\mathbf{t}_l$ is the predicted gene expression in tissue $l$, $\gamma_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Pass Reason: All assertions passed"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \appro \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes wrong latex expressions,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.31)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367] that approximates PrediXcan results using only GWAS summary statistics. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l} \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\gamma_l$ is the effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $z_{l}=\gamma_l / \mathrm{se}(\gamma_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using the expression

$$
z_{l} \approx \sum_{a \in \mathrm{model}_{l}} w_a^l \frac{\sigma_a}{\sigma_l} \frac{\beta_a}{\mathrm{se}(\beta_a)},
$$ {#eq:spredixcan}

where $\sigma_a$ is the variance of SNP $a$, $\sigma_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\beta_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. S-PrediXcan provides tissue-specific direction of effects, indicating whether a higher or lower predicted expression of a gene confers more or less disease risk. We used these $z$-scores in our drug repurposing approach, which is described below.

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size (regression coefficient), and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \appro \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes wrong latex expressions,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.31)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary-based version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l} \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\gamma_l$ is the effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $z_{l}=\gamma_l / \mathrm{se}(\gamma_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
z_{l} \approx \sum_{a \in \mathrm{model}_{l}} w_a^l \frac{\sigma_a}{\sigma_l} \frac{\beta_a}{\mathrm{se}(\beta_a)},
$$ {#eq:spredixcan}

where $\sigma_a$ is the variance of SNP $a$, $\sigma_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\beta_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model:

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression:

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \appro \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes wrong latex expressions,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.31)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367] that approximates PrediXcan results using only GWAS summary statistics. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l} \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\gamma_l$ is the effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $z_{l}=\gamma_l / \mathrm{se}(\gamma_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using the following expression:

$$
z_{l} \approx \sum_{a \in \mathrm{model}_{l}} w_a^l \frac{\sigma_a}{\sigma_l} \frac{\beta_a}{\mathrm{se}(\beta_a)},
$$ {#eq:spredixcan}

where $\sigma_a$ is the variance of SNP $a$, $\sigma_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\beta_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. S-PrediXcan provides tissue-specific direction of effects, indicating whether a higher or lower predicted expression of a gene confers more or less disease risk. We used these $z$-scores in our drug repurposing approach, which is described below.

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, while S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \appro \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes wrong latex expressions,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.31)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l} \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\gamma_l$ is the effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $z_{l}=\gamma_l / \mathrm{se}(\gamma_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
z_{l} \approx \sum_{a \in \mathrm{model}_{l}} w_a^l \frac{\sigma_a}{\sigma_l} \frac{\beta_a}{\mathrm{se}(\beta_a)},
$$ {#eq:spredixcan}

where $\sigma_a$ is the variance of SNP $a$, $\sigma_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\beta_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based extension of the PrediXcan method [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l} \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size (regression coefficient), and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l"
"S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models the trait as a linear function of the gene's expression on a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan needs individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only GWAS summary statistics with the expression

$$
\hat{z}_{l} \appro \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of SNP $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these TWAS methods, the genotype variances and covariances are always estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether a higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).","genetic studies, functional genomics, gene co-expression, therapeutic targets, drug repurposing, clustering of complex traits",Fixes wrong latex expressions,Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms,"[FAIL] (0.31)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
Here is the revised paragraph for the Methods section:

S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is the summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l} \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (for instance, whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary-based version of PrediXcan [@doi:10.1038/ng.3367], which models a trait as a linear function of a gene's expression in a single tissue using the univariate model:

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size or regression coefficient, and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. While PrediXcan requires individual-level data to fit this model, S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the following expression:

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. As S-PrediXcan provides tissue-specific direction of effects (e.g., whether a higher or lower predicted expression of a gene confers more or less disease risk), we utilized the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l","[FAIL] (0.34)

Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l 
---
S-PrediXcan [@doi:10.1038/s41467-018-03621-1] is a summary version of PrediXcan [@doi:10.1038/ng.3367]. PrediXcan models a trait as a linear function of a gene's expression in a single tissue using the univariate model

$$
\mathbf{y} = \mathbf{t_l \gamma_l + \bm{\epsilon}_l,
$$ {#eq:predixcan}

where $\hat{\gamma}_l$ is the estimated effect size (regression coefficient), and $\bm{\epsilon}_l$ are the error terms with variance $\sigma_{\epsilon}^{2}$. The significance of the association is assessed by computing the $z$-score $\hat{z}_{l}=\hat{\gamma}_l / \mathrm{se}(\hat{\gamma}_l)$ for a gene's tissue model $l$. PrediXcan requires individual-level data to fit this model, whereas S-PrediXcan approximates PrediXcan $z$-scores using only genome-wide association study (GWAS) summary statistics with the expression

$$
\hat{z}_{l} \approx \sum_{a \in model_{l}} w_a^l \frac{\hat{\sigma}_a}{\hat{\sigma}_l} \frac{\hat{\beta}_a}{\mathrm{se}(\hat{\beta}_a)},
$$ {#eq:spredixcan}

where $\hat{\sigma}_a$ is the variance of single nucleotide polymorphism (SNP) $a$, $\hat{\sigma}_l$ is the variance of the predicted expression of a gene in tissue $l$, and $\hat{\beta}_a$ is the estimated effect size of SNP $a$ from the GWAS. In these transcriptome-wide association study (TWAS) methods, the genotype variances and covariances are consistently estimated using the Genotype-Tissue Expression project (GTEx v8) [@doi:10.1126/science.aaz1776] as the reference panel. Since S-PrediXcan provides tissue-specific direction of effects (e.g., whether higher or lower predicted expression of a gene confers more or less disease risk), we used the $z$-scores in our drug repurposing approach (described below).

Fail Reason: Failed to fix the following expressions:
 - \mathbf{t_l  -> \mathbf{t}_l"
